TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 181.4M
Gross Profit 108.9M 60.02%
Operating Income 15.1M 8.34%
Net Income 9.7M 5.34%
EPS (Diluted) ₹8.06

Balance Sheet Metrics

Total Assets 743.2M
Total Liabilities 206.7M
Shareholders Equity 535.7M
Debt to Equity 0.39

Cash Flow Metrics

Revenue & Profitability Trend

Mercury Laboratories Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i751.0M755.6M753.3M579.2M686.0M
Cost of Goods Sold i289.2M305.4M306.1M237.6M313.8M
Gross Profit i461.9M450.2M447.3M341.6M372.3M
Gross Margin % i61.5%59.6%59.4%59.0%54.3%
Operating Expenses
Research & Development i-245.0K85.0K241.0K26.0K
Selling, General & Administrative i59.1M61.2M62.2M37.0M48.8M
Other Operating Expenses i124.9M138.3M151.3M105.9M108.3M
Total Operating Expenses i183.9M199.8M213.6M143.2M157.1M
Operating Income i74.1M76.6M66.0M47.8M92.2M
Operating Margin % i9.9%10.1%8.8%8.2%13.4%
Non-Operating Items
Interest Income i944.0K1.2M1.2M884.0K575.0K
Interest Expense i2.2M646.0K570.0K1.7M2.5M
Other Non-Operating Income-----
Pre-tax Income i46.6M69.2M74.4M50.3M79.1M
Income Tax i15.2M12.7M18.7M14.7M25.7M
Effective Tax Rate % i32.5%18.3%25.1%29.2%32.5%
Net Income i31.4M56.5M55.8M35.6M53.4M
Net Margin % i4.2%7.5%7.4%6.1%7.8%
Key Metrics
EBITDA i109.7M111.8M105.0M77.2M116.3M
EPS (Basic) i₹26.21₹47.12₹46.49₹29.68₹44.48
EPS (Diluted) i₹26.21₹47.12₹46.49₹29.68₹44.48
Basic Shares Outstanding i12000001200000120000012000001200000
Diluted Shares Outstanding i12000001200000120000012000001200000

Income Statement Trend

Mercury Laboratories Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i3.3M32.9M37.1M41.1M30.3M
Short-term Investments i13.0M48.0M31.5M21.2M11.5M
Accounts Receivable i257.4M218.5M213.7M167.4M225.4M
Inventory i72.1M62.1M69.0M67.8M51.6M
Other Current Assets47.2M33.4M55.6M42.5M47.5M
Total Current Assets i401.6M398.4M394.6M352.2M378.0M
Non-Current Assets
Property, Plant & Equipment i85.4M76.5M73.7M70.6M70.9M
Goodwill i263.0K254.0K408.0K562.0K838.0K
Intangible Assets i263.0K254.0K408.0K562.0K838.0K
Long-term Investments-----
Other Non-Current Assets1.9M2.7M14.7M13.9M12.1M
Total Non-Current Assets i341.6M281.2M247.1M272.1M275.7M
Total Assets i743.2M679.6M641.6M624.3M653.7M
Liabilities
Current Liabilities
Accounts Payable i98.3M51.8M63.8M68.7M117.8M
Short-term Debt i16.7M26.4M33.7M30.8M8.6M
Current Portion of Long-term Debt-----
Other Current Liabilities1.2M2.9M2.6M11.3M18.6M
Total Current Liabilities i150.8M129.4M141.8M157.5M188.3M
Non-Current Liabilities
Long-term Debt i37.8M29.2M24.7M29.0M62.4M
Deferred Tax Liabilities i14.3M12.6M18.9M22.3M21.3M
Other Non-Current Liabilities-2.0K-2.0K-2.0K1.0K-1.0K
Total Non-Current Liabilities i55.9M41.8M43.6M63.8M96.4M
Total Liabilities i206.7M171.2M185.3M221.2M284.8M
Equity
Common Stock i12.0M12.0M12.0M12.0M12.0M
Retained Earnings i86.6M59.3M42.0M25.4M29.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i535.7M508.4M456.3M403.1M368.9M
Key Metrics
Total Debt i54.5M55.5M58.3M59.9M71.0M
Working Capital i250.8M268.9M252.8M194.7M189.6M

Balance Sheet Composition

Mercury Laboratories Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i46.6M69.2M74.4M50.3M79.1M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-64.7M5.6M-62.0M38.5M-43.3M
Operating Cash Flow i-12.6M78.6M16.1M93.3M42.2M
Investing Activities
Capital Expenditures i-90.4M-62.7M-10.6M-18.9M-46.2M
Acquisitions i-----
Investment Purchases i--000
Investment Sales i--000
Investing Cash Flow i-90.4M-62.7M-10.6M-18.9M-46.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-4.2M-4.2M-4.2M-2.4M-4.2M
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i-19.2M-6.9M-2.1M-5.7M-5.1M
Free Cash Flow i-50.4M19.5M14.0M32.7M35.9M
Net Change in Cash i-122.3M9.0M3.4M68.7M-9.0M

Cash Flow Trend

Mercury Laboratories Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 26.09
Price to Book 1.84
Price to Sales 1.29
PEG Ratio 0.14

Profitability Ratios

Profit Margin 4.93%
Operating Margin 8.34%
Return on Equity 5.87%
Return on Assets 4.23%

Financial Health

Current Ratio 2.66
Debt to Equity 10.18
Beta 0.57

Per Share Data

EPS (TTM) ₹31.43
Book Value per Share ₹446.41
Revenue per Share ₹637.70

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mercurylab1.0B26.091.845.87%4.93%10.18
Sun Pharmaceutical 3.9T36.745.3015.08%19.29%3.26
Divi's Laboratories 1.6T65.3610.0914.64%23.89%0.03
Suven Life Sciences 48.2B-28.0140.49-146.15%84.44%0.00
Sequent Scientific 48.1B166.336.612.84%1.85%62.47
Aarti Drugs 44.5B23.663.2612.28%7.80%44.92

Financial data is updated regularly. All figures are in the company's reporting currency.